Ca breast - oncology - SA Health Approved Cancer Chemotherapy Protocol Register

Ca Breast
Protocol Administration at chemotherapy unit level Review Date
Breast trastuzumab subcutaneous Low February 2025

Adjuvant

Adjuvant
Protocol Administration at chemotherapy unit level Review Date
Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense Medium February 2025
Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) (dose dense) followed by PACLItaxel (dose dense) Medium February 2025
Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) followed by PACLItaxel (weekly) and trastuzumab (three weekly) Medium. Moves to low risk after completion of PACLitaxel treatment) February 2026
Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) followed by PACLItaxel (weekly) Medium February 2026
Breast adjuvant AC (DOXOrubicin CYCLOPHOSPHamide) three weekly Medium February 2026
Breast adjuvant anastrozole Low February 2026
Breast adjuvant anastrozole (early switch) Low February 2026
Breast adjuvant capecitabine (post neoadjuvant chemotherapy) Low February 2023
Breast adjuvant CMF classical (CYCLOPHOSPHamide methotrexate fluorouracil) Medium February 2025
Breast adjuvant D (DOCEtaxel) (Part 2 of FEC-D ) Medium September 2020
Breast adjuvant EC (epirubicin and CYCLOPHOSPHamide) Medium February 2025
Breast adjuvant exemestane Low February 2026
Breast adjuvant exemestane and goserelin Low February 2025
Breast adjuvant FEC (fluorouracil epirubicin CYCLOPHOSPHamide) (part 1 of FEC-D) Medium September 2020
Breast adjuvant FEC-D ((fluorouracil epirubicin CYCLOPHOSPHamide followed by DOCEtaxel) Medium September 2020
Breast adjuvant goserelin Low February 2024
Breast adjuvant letrozole Low February 2026
Breast adjuvant neratinib Low February 2023
Breast adjuvant PACLItaxel dose dense Medium February 2025
Breast adjuvant PACLItaxel weekly Medium February 2026
Breast adjuvant PACLItaxel weekly and trastuzumab three weekly Medium. Moves to low risk after completion of PACLitaxel treatment) February 2026
Breast adjuvant TAC (DOCEtaxel DOXOrubicin CYCLOPHOSPHamide) Medium February 2025
Breast adjuvant tamoxifen Low February 2025
Breast adjuvant TC (DOCEtaxel and CYCLOPHOSPHamide) Medium February 2025
Breast adjuvant TCH (DOCEtaxel cARBOplatin trastuzumab) Medium. Moves to low risk after completion of DOCEtaxel/cARBOplatin treatment) February 2025
Breast adjuvant TH (DOCEtaxel and trastuzumab) three weekly Medium. Moves to low risk after completion of DOCEtaxel treatment) February 2026
Breast adjuvant trastuzumab emtansine Medium August 2022
Breast adjuvant trastuzumab three weekly Low February 2025

Neoadjuvant

Neoadjuvant
Protocol Administration at chemotherapy unit level Review Date
Breast neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense (Part 2) Medium February 2025
Breast neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly Medium February 2025
Breast neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly followed by DOCEtaxel three weekly Medium February 2023
Breast neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly followed by PACLitaxel weekly overview Medium February 2025
Breast neoadjuvant cARBOplatin three weekly and PACLItaxel weekly (part 1) Medium February 2025
Breast Neoadjuvant cARBOplatin and PACLItaxel weekly – interim protocol
This protocol is intended to be linked with a course of anthracycline therapy (e.g. AC). (for information on this protocol please contact the SA Health Cancer Drug Committee
Medium November 2021
Breast neoadjuvant cARBOplatin three weekly and PACLItaxel weekly followed by AC (DOXOrubicin CYCLOPHOSPHamide) dose dense overview Medium February 2021
Breast neoadjuvant D (DOCEtaxel) (part 2 of FEC-D) Medium February 2023
Breast neoadjuvant DOCEtaxel three weekly (Part 2) Medium February 2023
Breast neoadjuvant DOCEtaxel, pertuzumab and trastuzumab Medium February 2022
Breast neoadjuvant FEC (fluorouracil epirubicin CYCLOPHOSPHamide) (Part 1 of FEC-D) Medium February 2023
Breast neoadjuvant PACLitaxel weekly (part 2) Medium February 2025
Breast neoadjuvant PACLitaxel weekly, pertuzumab and trastuzumab three weekly Medium February 2023
Breast neoadjuvant TAC (DOCEtaxel DOXOrubicin CYCLOPHOSPHamide) Medium February 2024
Breast neoadjuvant TCHP (DOCEtaxel, cARBOplatin, trastuzumab and pertuzumab)
Medium4 February 2022
Breast neoadjuvant trastuzumab three weekly Low February 2023

Metastatic

Metastatic
Protocol Administration at chemotherapy unit level Review Date
Advanced, metastatic or recurrent olaparib
Low February 2022
Breast metastatic abemaciclib3
Low February 2022
Breast metastatic AC (DOXOrubicin and CYCLOPHOSPHamide) Medium February 2025
Breast metastatic anastrozole Low February 2025
Breast metastatic capecitabine Low February 2022
Breast metastatic capecitabine and lapatinib Low February 2026
Breast metastatic capecitabine and trastuzumab Low February 2024
Breast metastatic cARBOplatin and Gemcitabine Medium, Day 1. Low, Day 8 February 2026
Breast metastatic CMF classical (CYCLOPHOSPHamide methotrexate fluorouracil) Medium February 2025
Breast metastatic denosumab Low February 2022
Breast metastatic DOCEtaxel and trastuzumab three weekly Medium. Moves to low risk after completion of DOCEtaxel treatment) February 2025
Breast metastatic DOCEtaxel three weekly Medium February 2025
Breast metastatic DOCEtaxel, pertuzumab and trastuzumab Medium. Moves to low risk after completion of DOCEtaxel treatment) February 2025
Breast metastatic DOXOrubicin three weekly Medium February 2025
Breast metastatic DOXOrubicin weekly Medium February 2025
Breast metastatic epirubicin weekly. For information on this protocol please contact the SA Health Cancer Drug Committee) Medium December 2021
Breast metastatic EC (epirubicin and CYCLOPHOSPHamide) Medium February 2025
Breast metastatic eribulin Medium February 2025
Breast metastatic everolimus and exemestane Low February 2022
Breast metastatic exemestane Low February 2025
Breast metastatic fulvestrant3 Medium February 2022
Breast metastatic goserelin Low February 2025
Breast metastatic letrozole Low February 2025
Breast metastatic nab-PACLItaxel weekly Medium February 2025
Breast metastatic PACLItaxel weekly Medium February 2025
Breast metastatic PACLItaxel weekly and trastuzumab three weekly Medium. Moves to low risk after completion of PACLitaxel treatment) February 2025
Breast metastatic PACLItaxel weekly, pertuzumab and trastuzumab three weekly Medium4  February 2022
Breast metastatic palbociclib Low February 2022
Breast metastatic pegylated liposomal DOXOrubicin Medium February 2025
Breast metastatic ribociclib Low February 2022
Breast metastatic tamoxifen Low February 2025
Breast metastatic trastuzumab emtansine Medium1 February 2024
Breast metastatic trastuzumab three weekly Low February 2025
Breast metastatic trastuzumab three weekly and vinORELBine (IV) Medium. Moves to low risk after completion of vinORELbine treatment) February 2026
Breast metastatic trastuzumab three weekly and vinORELBine (oral) Low February 2025
Breast metastatic vinORELBine (IV) Medium February 2025
Breast metastatic vinORELBine (oral) Low February 2025
Breast metastatic zoledronic acid Low February 2022

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.